Work

Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors

Year: 2022

Type: review

Source: Hematology/Oncology Clinics of North America

DOI: 10.1016/j.hoc.2022.07.008

Authors: Anu Chittenden, Sigurdis Haraldsdottir, Ethan Chen, Sahar Nissim

Institutions: Dana-Farber Cancer Institute, University of Iceland, National University Hospital of Iceland, Brigham and Women's Hospital, Harvard University, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Institute of Diabetes and Digestive and Kidney Diseases

Award: The Impacts of NR5A2 Pharmacologic Agonism on Pancreas Development and Disease

OpenAlex ID: W4306662703

FWCI:

Cites: 135

Cited by:

Related to: 10